Keywords: Celgene, Revlimid, Pomalidomide, EMA, Multiple myeloma, Financial guidance

Celgene slumps as it pulls new EU indication filing for Revlimid

Article | 22 June 2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided a regulatory update for Revlimid (lenalidomide) and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Celgene

Go to company listing

Related Drugs

Revlimid

pomalidomide

Go to drug listing